Overview

Teriparatide and Strontium Ranelate Head-To-Head Comparison Trial

Status:
Completed
Trial end date:
2007-01-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to directly compare the bone forming effects of 20 microg/day of teriparatide with those of 2 g/day strontium ranelate as measured by the histomorphometric variables and biochemical bone formation markers after 6 months of therapy in postmenopausal women with osteoporosis.
Phase:
Phase 4
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Strontium ranelate
Teriparatide